Dermatological aspects of angiogenesis

British Journal of Dermatology

Volumn 147, Issue 5, 2002, Pages 841-852

  Velasco, P ^a   Lange Asschenfeldt, Bernhard ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Angiogenesis; Angiogenesis inhibitors; Lymphangiogenesis; Skin; Tumour; Vascular endothelial growth factor

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BEVACIZUMAB; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 12; LENALIDOMIDE; REBIMASTAT; SEMAXANIB; THALIDOMIDE; UNCLASSIFIED DRUG; VASOSTATIN;

ANGIOGENESIS; BASAL CELL CARCINOMA; BONE MARROW CELL; CANCER INVASION; CLINICAL TRIAL; DOWN REGULATION; ENDOTHELIUM CELL; HEMANGIOMA; HUMAN; KAPOSI SARCOMA; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; SKIN CARCINOMA; SKIN LYMPHOMA; SOLID TUMOR; SPROUTING; SQUAMOUS CELL CARCINOMA; STEM CELL; T CELL LYMPHOMA; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CARCINOMA, SQUAMOUS CELL; HUMANS; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS;

EID: 0036438783     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.05073.x     Document Type: Review

References (135)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
2. Malhotra R, Stenn KS, Fernandez LA et al. Angiogenic properties of normal and psoriatic skin associate with epidermis, not dermis. Lab Invest 1989; 61: 162-5.
3. Ensoli B, Nakamura S, Salahuddin SZ et al. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 1989; 243: 223-6.
4. Graeven U, Rodeck U, Karpinski S et al. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res 2001; 61: 7282-90.
5. Chang J, Most D, Bresnick S et al. Proliferative hemangiomas: Analysis of cytokine gene expression and angiogenesis. Plast Reconstr Surg 1999; 103: 1-9, discussion 10.
6. Masood R, Cai J, Tulpule A et al. Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma. Clin Cancer Res 2001; 7: 2693-702.
7. Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 2000; 60: 4932-8.
8. Detmar M. The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci 2000; 24 (Suppl. 1): S78-84.
9. Houck KA, Ferrara N, Winer J et al. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5: 1806-14.
10. Terman BI, Carrion ME, Kovacs E et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991; 6: 1677-83.
11. De Vries C, Escobedo J, Ueno H et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-91.
12. Quinn TP, Peters KG, De Vries C et al. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 1993; 90: 7533-7.
13. Soker S, Gollamudi PS, Fidder H et al. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J Biol Chem 1997; 272: 31582-8.
14. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001; 106: 148-56.
15. Potgens AJ, Lubsen NH, van Altena MC et al. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 1995; 146: 197-209.
16. Staibano S, Boscaino A, Salvatore G et al. The prognostic significance of tumor angiogenesis in nonaggressive and aggressive basal cell carcinoma of the human skin. Hum Pathol 1996; 27: 695-700.
17. Detmar M, Velasco P, Richard L et al. Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas. Am J Pathol 2000; 156: 159-67.
18. Zucker S, Mirza H, Conner CE et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998; 75: 780-6.
19. Vu TH, Shipley JM, Bergers G et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93: 411-22.
20. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
21. Thurston G, Rudge JS, Ioffe E et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6: 460-3.
22. Pomyje J, Zivny JH, Stopka T et al. Angiopoietin-1, angiopoietin-2 and Tie-2 in tumour and non-tumour tissues during growth of experimental melanoma. Melanoma Res 2001; 11: 639-43.
23. Maisonpierre PC, Goldfarb M, Yancopoulos GD et al. Distinct rat genes with related profiles of expression define a TIE receptor tyrosine kinase family. Oncogene 1993; 8: 1631-7.
24. Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-8.
25. Vajkoczy P, Farhadi M, Gaumann A et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 2002; 109: 777-85.
26. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
27. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 2001; 107: 409-17.
28. Detmar M. Molecular regulation of angiogenesis in the skin. J Invest Dermatol 1996; 106: 207-8.
29. Hawighorst T, Velasco P, Streit M et al. Thrombospondin-2 plays a protective role in multistep carcinogenesis: A novel host antitumor defense mechanism. Embo J 2001; 20: 2631-40.
30. Wight TN, Raugi GJ, Mumby SM et al. Light microscopic immunolocation of thrombospondin in human tissues. J Histochem Cytochem 1985; 33: 295-302.
31. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994; 54: 6504-11.
32. Bleuel K, Popp S, Fusenig NE et al. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc Natl Acad Sci USA 1999; 96: 2065-70.
33. Streit M, Riccardi L, Velasco P et al. Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 1999; 96: 14888-93.
34. Streit M, Velasco P, Brown LF et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999; 155: 441-52.
35. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
36. Pike SE, Yao L, Jones KD et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998; 188: 2349-56.
37. Yao L, Pike SE, Setsuda J et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 2000; 96: 1900-5.
38. Pepper MS. Lymphangiogenesis and tumor metastasis: Myth or reality? Clin Cancer Res 2001; 7: 462-8.
39. Joukov V, Pajusola K, Kaipainen A et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo J 1996; 15: 290-8.
40. Lee J, Gray A, Yuan J et al. Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 1996; 93: 1988-92.
41. Skobe M, Hamberg LM, Hawighorst T et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001; 159: 893-903.
42. Skobe M, Hawighorst T, Jackson DG et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-8.
43. Mandriota SJ, Jussila L, Jeltsch M et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001; 20: 672-82.
44. Karpanen T, Egeblad M, Karkkainen MJ et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001; 61: 1786-90.
45. Jackson DG, Prevo R, Clasper S et al. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 2001; 22: 317-21.
46. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999; 98: 769-78.
47. Marchuk DA. Pathogenesis of hemangioma. J Clin Invest 2001; 107: 665-6.
48. Takahashi K, Mulliken JB, Kozakewich HP et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93: 2357-64.
49. Salcedo R, Ponce ML, Young HA et al. Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96: 34-40.
50. Yu Y, Varughese J, Brown LF et al. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 2001; 159: 2271-80.
51. Vikkula M, Boon LM, Carraway KL III et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996; 87: 1181-90.
52. Bielenberg DR, Bucana CD, Sanchez R et al. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Int J Oncol 1999; 14: 401-8.
53. Lannutti BJ, Gately ST, Quevedo ME et al. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 1997; 57: 5277-80.
54. Vergani V, Garofalo A, Bani MR et al. Inhibition of matrix metalloproteinases by overexpression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas. Int J Cancer 2001; 91: 241-7.
55. Ramakrishnan S, Olson TA, Bautch VL et al. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996; 56: 1324-30.
56. Liekens S, Verbeken E, Vandeputte M et al. A novel animal model for hemangiomas: Inhibition of hemangioma development by the angiogenesis inhibitor TNP-470. Cancer Res 1999; 59: 2376-83.
57. Taraboletti G, Garofalo A, Belotti D et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995; 87: 293-8.
58. Regezi JA, MacPhail LA, Daniels TE et al. Human immunodeficiency virus-associated oral Kaposi's sarcoma. A heterogeneous cell population dominated by spindle-shaped endothelial cells. Am J Pathol 1993; 143: 240-9.
59. Safai B, Johnson KG, Myskowski PL et al. The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103: 744-50.
60. Sturzl M, Brandstetter H, Roth WK. Kaposi's sarcoma: A review of gene expression and ultrastructure of KS spindle cells in vivo. AIDS Res Hum Retroviruses 1992; 8: 1753-63.
61. Masood R, Cai J, Zheng T et al. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA 1996; 93: 10589-94.
62. Miles SA, Rezai AR, Salazar-Gonzalez JF et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 1990; 87: 4068-72.
63. Brown LF, Dezube BJ, Tognazzi K et al. Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 2000; 156: 2179-83.
64. Skobe M, Brown LF, Tognazzi K et al. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J Invest Dermatol 1999; 113: 1047-53.
65. Marchio S, Primo L, Pagano M et al. Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells. J Biol Chem 1999; 274: 27617-22.
66. Sirianni MC, Vincenzi L, Fiorelli V et al. Gamma-interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: Correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages. Blood 1998; 91: 968-76.
67. Masood R, Cesarman E, Smith DL et al. Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am J Pathol 2002; 160: 23-9.
68. Albini A, Barillari G, Benelli R et al. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA 1995; 92: 4838-42.
69. Fiorelli V, Barillari G, Toschi E et al. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: Implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1999; 162: 1165-70.
70. Taraboletti G, Benelli R, Borsotti P et al. Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. J Pathol 1999; 188: 76-81.
71. Albini A, Marchisone C, Del Grosso F et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach. Am J Pathol 2000; 156: 1381-93.
72. Iurlaro M, Benelli R, Masiello L et al. Beta interferon inhibits HIV-1 Tat-induced angiogenesis: Synergism with 13-cis retinoic acid. Eur J Cancer 1998; 34: 570-6.
73. Incardona F, Lewalle JM, Morandi V et al. Thrombospondin modulates human breast adenocarcinoma cell adhesion to human vascular endothelial cells. Cancer Res 1995; 55: 166-73.
74. Pati S, Lee Y, Samaniego F. Urinary proteins with pro-apoptotic and antitumor activity. Apoptosis 2000; 5: 21-8.
75. Indraccolo S, Morini M, Gola E et al. Effects of angiostatin gene transfer on functional properties and in vivo growth of Kaposi's sarcoma cells. Cancer Res 2001; 61: 5441-6.
76. Sgadari C, Barillari G, Toschi E et al. HIV protease inhibitors are potent antiangiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8: 225-32.
77. Moore JD, Dezube BJ, Gill P et al. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma. Cancer Chemother Pharmacol 2000; 46: 173-9.
78. Tulpule A, Scadden DT, Espina BM et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18: 716-23.
79. Albini A, Morini M, D'Agostini F et al. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res 2001; 61: 8171-8.
80. Aluigi MG, De Flora S, D'Agostini F et al. Antiapoptotic and antigenotoxic effects of N-acetylcysteine in human cells of endothelial origin. Anticancer Res 2000; 20: 3183-7.
81. Antonian L, Zhang H, Yang C et al. Biotransformation of the antiangiogenic compound SU5416. Drug Metab Dispos 2000; 28: 1505-12.
82. Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur J Cancer 2001; 37: 1288-95.
83. Arbiser JL, Panigrathy D, Klauber N et al. The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. J Am Acad Dermatol 1999; 40: 925-9.
84. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; i: 795-7.
85. Ziegler A, Jonason AS, Leffell DJ et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-6.
86. Skobe M, Rockwell P, Goldstein N et al. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997; 3: 1222-7.
87. Strieth S, Hartschuh W, Pilz L et al. Angiogenic switch occurs late in squamous cell carcinomas of human skin. Br J Cancer 2000; 82: 591-600.
88. Streit M, Stephen AE, Hawighorst T et al. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res 2002; 62: 2004-12.
89. Hawighorst T, Skobe M, Streit M et al. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 2002; 160: 1381-92.
90. Darland DC, D'Amore PA. Blood vessel maturation: Vascular development comes of age. J Clin Invest 1999; 103: 157-8.
91. Eberhard A, Kahlert S, Goede V et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-93.
92. Korff T, Kimmina S, Martiny-Baron G et al. Blood vessel maturation in a 3-dimensional spheroidal coculture model: Direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J 2001; 15: 447-57.
93. Lange-Asschenfeldt B, Velasco P, Streit M et al. The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses. J Invest Dermatol 2001; 117: 1036-41.
94. Arbiser JL. Melanoma. Lessons from metastases. Arch Dermatol 1998; 134: 1027-8.
95. Claffey KP, Brown LF, del Aguila LF et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56: 172-81.
96. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997; 76: 930-4.
97. Graeven U, Rodeck U, Karpinski S et al. Expression patterns of placenta growth factor in human melanocytic cell lines. J Invest Dermatol 2000; 115: 118-23.
98. Siemeister G, Schirner M, Weindel K et al. Two independent mechanisms essential for tumor angiogenesis: Inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 1999; 59: 3185-91.
99. Lin P, Buxton JA, Acheson A et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998; 95: 8829-34.
100. Albelda SM, Mette SA, Elder DE et al. Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression. Cancer Res 1990; 50: 6757-64.
101. Mitjans F, Meyer T, Fittschen C et al. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 2000; 87: 716-23.
102. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-71.
103. Rofstad EK, Graff BA. Thrombospondin-1-mediated metastasis suppression by the primary tumor in human melanoma xenografts. J Invest Dermatol 2001; 117: 1042-9.
104. Miao WM, Seng WL, Duquette M et al. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res 2001; 61: 7830-9.
105. Gee MS, Koch CJ, Evans SM et al. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res 1999; 59: 4882-9.
106. Stack MS, Gately S, Bafetti LM et al. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 1999; 340: 77-84.
107. Yamanaka R, Zullo SA, Ramsey J et al. Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Cancer Gene Ther 2001; 8: 796-802.
108. Yamaoka M, Yamamoto T, Masaki T et al. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Res 1993; 53: 4262-7.
109. Hwu WJ. New approaches in the treatment of metastatic melanoma: Thalidomide and temozolomide. Oncology (Huntingt) 2000; 14: 25-8.
110. Laird AD, Vajkoczy P, Shawver LK et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60: 4152-60.
111. Mah-Becherel MC, Ceraline J, Deplanque G et al. Antiangiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model. Br J Cancer 2002; 86: 803-10.
112. Wylie S, MacDonald IC, Varghese HJ et al. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin Exp Metastasis 1999; 17: 111-17.
113. Krüger A, Soeltl R, Sopov I et al. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 2001; 61: 1272-5.
114. Salven P, Lymboussaki A, Heikkila P et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 1998; 153: 103-8.
115. Achen MG, Williams RA, Minekus MP et al. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol 2001; 193: 147-54.
116. Stacker SA, Caesar C, Baldwin ME et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-91.
117. Bedlow AJ, Stanton AW, Cliff S et al. Basal cell carcinoma - An in-vivo model of human tumour microcirculation? Exp Dermatol 1999; 8: 222-6.
118. Vacca A, Moretti S, Ribatti D et al. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer 1997; 33: 1685-92.
119. Schaerer L, Schmid MH, Mueller B et al. Angiogenesis in cutaneous lymphoproliferative disorders: Microvessel density discriminates between cutaneous B-cell lymphomas and B-cell pseudolymphomas. Am J Dermatopathol 2000; 22: 140-3.
120. Boehm T, Folkman J, Browder T et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-7.
121. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 1996;: 167-90.
122. Carrau RL, Barnes EL, Snyderman CH et al. Tumor angiogenesis as a predictor of tumor aggressiveness and metastatic potential in squamous cell carcinoma of the head and neck. Invasion Metastasis 1995; 15: 197-202.
123. Tahan SR, Stein AL. Angiogenesis in invasive squamous cell carcinoma of the lip: Tumor vascularity is not an indicator of metastatic risk. J Cutan Pathol 1995; 22: 236-40.
124. Weninger W, Uthman A, Pammer J et al. Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors. Lab Invest 1996; 75: 647-57.
125. Weninger W, Rendl M, Pammer J et al. Differences in tumor microvessel density between squamous cell carcinomas and basal cell carcinomas may relate to their different biologic behavior. J Cutan Pathol 1997; 24: 364-9.
126. Ugurel S, Rappl G, Tilgen W et al. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19: 577-83.
127. Lauria R, Perrone F, Carlomagno C et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 1995; 76: 1772-8.
128. Little RF, Wyvill KM, Pluda JM et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18: 2593-602.
129. Kohn EC, Reed E, Sarosy G et al. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 1996; 56: 569-73.
130. Kohn EC, Figg WD, Sarosy GA et al. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: Pharmacokinetics, clinical outcome, and comparison of formulations. J Clin Oncol 1997; 15: 1985-93.
131. Klein SA, Bond SJ, Gupta SC et al. Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. J Surg Res 1999; 82: 268-74.
132. Bloch W, Huggel K, Sasaki T et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J 2000; 14: 2373-6.
133. Jacobson BS, Stolz DB, Schnitzer JE. Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease. Nat Med 1996; 2: 482-4.
134. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993; 90: 8996-9000.
135. Yano K, Oura H, Detmar M. Targeted overexpression of the angiogenesis inhibitor thrombospondin-1 in the epidermis of transgenic mice prevents ultraviolet-B-induced angiogenesis and cutaneous photo-damage. J Invest Dermatol 2002; 118: 800-5.